TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Quantum Biopharma Ltd.
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Quantum BioPharma announced completion of oral dosing in 180-day repeated dose toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), a first-in-class treatment candidate for multiple sclerosis. The studies will support the company's Investigational New Drug (IND) application with the US FDA and inform the design of a Phase 2 trial. Lucid-MS is designed to prevent myelin degradation and disease progression in MS patients.

Insights
BAC   neutral

Mentioned as having a speaker (Arshad Ghafur) at the forum, with no specific positive or negative context


QNTM   positive

Completion of critical 180-day toxicity studies represents significant progress in the drug development pipeline. These studies are essential regulatory milestones that advance the company closer to FDA IND approval and Phase 2 clinical trials for a first-in-class MS treatment, demonstrating operational execution and de-risking of the development program.